Drug General Information |
Drug ID |
D06PJW
|
Former ID |
DIB019946
|
Drug Name |
GSK-1838705A
|
Synonyms |
GSK 1838705A; GSK1838705A
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
|
Formula |
C27H29FN8O3
|
InChI |
InChI=1S/C27H29FN8O3/c1-29-26(38)23-17(28)6-5-7-18(23)31-25-16-8-10-30-24(16)33-27(34-25)32-19-13-20-15(12-21(19)39-4)9-11-36(20)22(37)14-35(2)3/h5-8,10,12-13H,9,11,14H2,1-4H3,(H,29,38)(H3,30,31,32,33,34)
|
InChIKey |
HZTYDQRUAWIZRE-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
57290284, 57560329, 85028021, 103629211, 136348846, 136349563, 136367694, 141017575, 144116027, 152258421, 160647257, 162011614, 162038108, 162202695, 174006568, 174526213, 178102310, 180408479, 185990476, 189622850, 223705044, 224416783, 228335086, 237498825, 241377333, 242059764, 245173602, 247813672, 251963084, 252158607, 252160876, 252215504, 252443407, 252451201, 252671615
|
Target and Pathway |
Target(s) |
ribosomal protein S6 kinase, 90kDa, polypeptide 1 |
Target Info |
Inhibitor |
[1]
|
Insulin receptor |
Target Info |
Inhibitor |
[1]
|
ALK tyrosine kinase receptor |
Target Info |
Inhibitor |
[1]
|
mRNA of Insulin-like growth factor 1 receptor |
Target Info |
Inhibitor |
[2]
|
KEGG Pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
cGMP-PKG signaling pathway
|
HIF-1 signaling pathway
|
FoxO signaling pathway
|
PI3K-Akt signaling pathway
|
AMPK signaling pathway
|
Adherens junction
|
Insulin signaling pathway
|
Ovarian steroidogenesis
|
Type II diabetes mellitus
|
Non-alcoholic fatty liver disease (NAFLD)
|
Aldosterone-regulated sodium reabsorptionhsa05223:Non-small cell lung cancerhsa04014:Ras signaling pathway
|
Oocyte meiosis
|
Endocytosis
|
Focal adhesion
|
Signaling pathways regulating pluripotency of stem cells
|
Long-term depression
|
Progesterone-mediated oocyte maturation
|
Pathways in cancer
|
Transcriptional misregulation in cancer
|
Proteoglycans in cancer
|
Glioma
|
Prostate cancer
|
Melanoma
|
NetPath Pathway
|
TGF_beta_Receptor Signaling Pathway
|
PANTHER Pathway
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
Insulin/IGF pathway-protein kinase B signaling cascade
|
PI3 kinase pathwayP00032:Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
Pathway Interaction Database
|
Insulin Pathway
|
Signaling events mediated by PTP1B
|
Signaling events mediated by TCPTP
|
Insulin-mediated glucose transporter_nongenomic_pathway:Plasma membrane estrogen receptor signaling
|
SHP2 signaling
|
IGF1 pathway
|
Posttranslational regulation of adherens junction stability and dissassembly
|
Integrins in angiogenesis
|
Stabilization and expansion of the E-cadherin adherens junction
|
PathWhiz Pathway
|
Insulin Signalling
|
Leucine Stimulation on Insulin Signaling
|
Reactome
|
IRS activation
|
Signal attenuation
|
Insulin receptor signalling cascade
|
Insulin receptor recyclingR-HSA-2428928:IRS-related events triggered by IGF1R
|
SHC-related events triggered by IGF1R
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
Insulin Signaling
|
Nanoparticle triggered autophagic cell death
|
AGE/RAGE pathway
|
Signaling by Insulin receptor
|
Folate Metabolism
|
Type II diabetes mellitus
|
Vitamin B12 Metabolism
|
Selenium Micronutrient Network
|
AMPK SignalingWP2848:Differentiation PathwayWP615:Senescence and Autophagy in Cancer
|
Endochondral Ossification
|
Focal Adhesion
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
Apoptosis
|
Signaling Pathways in Glioblastoma
|
TSH signaling pathway
|
MicroRNAs in cardiomyocyte hypertrophy
|
References |
REF 1 | GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009 Oct;8(10):2811-20. |
---|
REF 2 | Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51. |